A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...

Intellia Therapeutics stock crashed Friday after a patient in its gene-editing study died following serious increases in liver enzymes.

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Dolphins living along Florida’s coast appear to be affected by the same types of environmental factors that are being ...

Intellia Therapeutics (NTLA) stock plummets after the company's Q3 updates indicate a patient deeath in a Phase 3 for its nex ...

Lowering the transcription factor PU.1 reprograms microglia into a neuroprotective, lymphoid-like state that compacts amyloid ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on ...

Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 ...

New diagnostic kits aim to revolutionize early screening of the disease, potentially allowing patients to receive ...